An extensive survey by Deloitte reveals life sciences firms confronting significant strategic and operational impacts due to evolving tariffs and pricing policies globally. About two-thirds of respondents anticipate moderate to major effects on commercial planning, with many companies bolstering supply chains and scenario-planning efforts. However, only a minority have restructured organizationally, indicating room for enhanced operational adaptation. Findings emphasize the need for integrated, agile responses as firms navigate complex regulatory and economic uncertainties shaping the biotech and pharmaceutical landscapes.